Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF known ✓ | P15056 | 6/20 | 0.54 |
| ▸ | KDR known ✓ | P35968 | 5/20 | 0.54 |
| ▸ | KIT known ✓ | P10721 | 1/20 | 0.49 |
| ▸ | KRAS | P01116 | 5/20 | 0.54 |
| ▸ | RAF1 | P04049 | 5/20 | 0.54 |
| ▸ | MAP2K2 | P36507 | 3/20 | 0.54 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.54 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.45 |
| ▸ | SRC | P12931 | 4/20 | 0.45 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.43 |
| ▸ | LYN | P07948 | 4/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5062493 | 0.97 | BRAF (0.56) | BRAFKRASRAF1KDRMAP2K2 | |
| SCHEMBL5065396 | 0.85 | BRAF (0.57) | BRAFKRASRAF1KDRMAP2K2 | |
| SCHEMBL5057379 | 0.84 | SRC (0.49) | BRAFKRASRAF1KDRMAP2K2 | |
| SCHEMBL4566603 | 0.80 | BRAF (0.52) | BRAFKRASRAF1KDRMAP2K2 | |
| SCHEMBL4280916 | 0.80 | BRAF (0.57) | BRAFKRASRAF1KDRMAP2K2 | |
| SCHEMBL4417045 | 0.80 | KDR (0.53) | BRAFKRASRAF1KDRMAP2K2 | |
| SCHEMBL4430449 | 0.80 | BRAF (0.58) | BRAFKRASRAF1KDRMAP2K2 | |
| SCHEMBL4566548 | 0.80 | BRAF (0.53) | BRAFKRASRAF1KDRMAP2K2 | |
| SCHEMBL5057547 | 0.79 | BRAF (0.61) | BRAFKRASRAF1KDRMAP2K2 | |
| SCHEMBL5061319 | 0.79 | BRAF (0.55) | BRAFKRASRAF1KDRMAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120289540-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-11-15 | — | — | US | disclosed |
| US-8188113-B2 | For example, 1-(5-(2-amino-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl)-3-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20080114006-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289540-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | BRAF, PRKDC, RAF1 | BRAF 1/4885KDR 500/4885KIT 2755/4885 |
| US-20080114006-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | BRAF, PRKDC, RAF1 | BRAF 1/4885KDR 500/4885KIT 2755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.